With M&A deals percolating around the global biopharma industry, investors bought in to the story anyway, driving up Chugai's stock price to record levels on the market buzz as fresh press reports added to the speculative frenzy.
Just last month Roche CEO Severin Schwan indicated he wasn't interested in mega-deals to build his company, only smaller, more targeted buys. Of course what is targeted and what is mega is in the eyes of the beholder. The Swiss drugmaker is reportedly in talks to buy up the 40% piece of Japanese partner Chugai Pharmaceutical it doesn't currently own. Price? $10 billion.
Roche is taking a hard look at partner Chugai Pharmaceutical, according to a report, considering whether to pay about $10 billion to buy the remaining shares of the company.
Go ahead and investigate Valeant and Pershing Square Capital Management, the drugmaker's deal partner in its $54 billion hostile bid for Allergan, the pair said Thursday in response to a reported SEC probe over insider trading. According to them, they've got nothing to hide.
As InterMune awaits FDA approval for its drug to treat a rare lung disease, reports emerged Wednesday that it has hired financial advisers to weigh takeover bids from the likes of Sanofi and Roche.
Basilea CEO Ronald Scott offered that the next best step for the biotech may be to just sell the Basel-based company to a U.S.-based biopharma company interested in a quick tax inversion deal that would allow a buyer the chance of trading American taxes for a sweeter deal in Switzerland.
Amid its fight to stave off a hostile takeover, Botox maker Allergan is making a buy of its own, trading up to $587.5 million for a midstage bladder drug from the biotech Taris.
InterMune's promising treatment for a rare lung disease has put it in Big Pharma's crosshairs, according to a report, news that sent the biotech's shares soaring as much as 20% on Wednesday.
Merck KGaA is talking up deals again, pointing to its healthy cash reserves and saying it can well afford a blockbuster buyout to bolster its pipeline. But that's been the story for nearly a year, so what's the German giant waiting on?
A top Valeant shareholder isn't saying the company can't win its hostile $53 billion takeover battle for Allergan. It's just saying it doesn't need to.